• English
  • Deutsch
  • More Info
  • Treatment of PE
  • Causes of PE
  • Impact of PE
  • What is PE
  • Home

Disclaimer

About Premature Ejaculation (PE) Website is owned and managed by Auris Medtech Europe Limited.
 
Auris Medtech Europe Limited (‘AMEL’) does not have any direct knowledge of or affiliation with the advertisers and practitioners, or the services and products they provide, which are published on the About Premature Ejaculation (PE) Website (‘the Website’). AMEL bears no responsibility for the information published on the Website that concerns or relates to advertisers.  AMEL bears no responsibility for the content of third party websites accessed through links on the Website. Information relating to advertisers and links to third party websites is provided for reference purposes only.

All and any information published on the Website that relates to advertisers, is provided with the permission of the advertisers. Any information written by AMEL on behalf of advertisers is checked and approved by the advertisers prior to publication. AMEL does not verify the accuracy of the information provided by advertisers and makes no warranties as to the accuracy of such information.

While AMEL has no reason to believe that there are inaccuracies or defects in any of the information published on the Website, it makes no representations or warranties, express or implied, including but not limited to the fitness of the information for any purpose whatsoever. In providing the information to users, no contractual obligation is or has been constituted between the user and AMEL and no duty of care is owed to the user. If a court rules that AMEL in fact owes a duty of care to the user, AMEL will not be liable for any direct or indirect consequences, loss or damages arising from use of this information arising as a result of AMEL’s negligence.

The information on the Website should not be used as a basis for diagnosis, choice of treatment or choice of medical practitioner. It is intended that the information published on the Website shall enable users to conduct their own research into the advertisers, their services and their products.

Any representations or recommendations made by employees of AMEL, be it oral, written or via email, should not be relied upon.




  • News from around the world …

    Ampio announces positive results from 12-week open label extension study of Zertane(TM) in patients with premature ejaculation
  • Disclaimer
  • Terms of Use
  • Cookies and Privacy Policy
© 2012. All rights reserved.